Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19077685 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | March 2025 | May 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18977838 | LEONURINE NANOCOMPOSITE HYDROGEL AND PREPARATION METHODS AND APPLICATIONS THEREOF | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18761898 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18762128 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | February 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18565894 | CATIONIC LIPID COMPOUND, COMPOSITION CONTAINING SAME AND USE THEREOF | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18546845 | USE OF CATIONIC PORPHYRINS AS SELECTIVE HERBICIDE | August 2023 | December 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18357485 | Compounds, Pharmaceuticals, Formulations, and Methods for Treating and Preventing RNA Virus Infections and Associated Diseases | July 2023 | March 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18255498 | HYDRATING COMPOSITION COMPRISING POLYMERS AND A COMPOUND CHOSEN FROM MENTHOL AND ITS DERIVATIVES | June 2023 | February 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18202981 | LIPOSOMIC DRUG-DELIVERY VEHICLES | May 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18038871 | PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAME | May 2023 | July 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18321613 | PREPARATION METHOD AND APPLICATION OF TUMOR MICROPARTICLES ENCAPSULATING METABOLIC INHIBITORS | May 2023 | June 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18247976 | IMPROVED PROCESS AND FORMULATION OF LIPID NANOPARTICLES | April 2023 | March 2026 | Allow | 35 | 2 | 0 | No | No |
| 18028614 | COMBINATIONS OF TRIAZINONE HERBICIDES WITH SAFENERS | March 2023 | March 2026 | Abandon | 35 | 2 | 0 | No | No |
| 18028617 | LIPID COMPOSITIONS COMPRISING POLYNUCLEOTIDE ANTIGENS | March 2023 | January 2026 | Abandon | 33 | 1 | 0 | No | No |
| 17909486 | METHOD FOR PREPARING A FORMULATION FOR INDUCING AN IMMUNE RESPONSE OF A PLANT TO A PATHOGEN, AND FORMULATION | March 2023 | August 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 18112720 | REDUCING HYDROPHOBIC DRUG ADSORPTION IN ECMO CIRCUITS | February 2023 | December 2025 | Abandon | 33 | 1 | 0 | No | No |
| 18021705 | METHOD OF MODULATING SENSITIVITY TO TYROSINE KINASE INHIBITOR | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18019685 | PLANT PATHOGEN DEFENCE ELICITORS | February 2023 | January 2026 | Allow | 35 | 0 | 0 | Yes | No |
| 18160263 | Encapsulation of cannabinoids | January 2023 | September 2025 | Abandon | 32 | 4 | 1 | No | No |
| 18016865 | RAPAMYCIN (RAPA) FORMULATION AND PREPARATION METHOD THEREOF | January 2023 | November 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18156534 | SKIN WHITENING COMPOSITION | January 2023 | April 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18081752 | COSMETIC COMPOSITION COMPRISING POLYACRYLATE CROSSPOLYMER-6, AND SILICA AND/OR LAUROYL LYSINE | December 2022 | February 2025 | Abandon | 26 | 3 | 0 | No | No |
| 17994217 | SUSTAINED-RELEASE PHEROMONE PREPARATION | November 2022 | June 2025 | Allow | 30 | 3 | 0 | Yes | No |
| 17999916 | NOVEL METHACRYLATE COPOLYMER AND COMPOSITIONS COMPRISING IT | November 2022 | July 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 17997850 | BEAUTY MICRONEEDLE ARRAY | November 2022 | November 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17979303 | COSMETIC PRODUCT COMPRISING OIL DISCONTINUOUS PHASE AND METHOD OF USE THEREOF | November 2022 | May 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17978667 | PRODUCTION PROCESS OF A CONVENIENT AND QUICK-ADHESIVE EYELASHES | November 2022 | April 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18049535 | POLYMERIC DELIVERY SYSTEMS | October 2022 | October 2025 | Allow | 45 | 3 | 1 | Yes | No |
| 17920582 | Nanotherapy Targeting RHAMM-Positive Tumors | October 2022 | January 2026 | Allow | 39 | 1 | 0 | Yes | No |
| 17970649 | SKIN HEALTH PRESERVATION TREATMENT FORMULATION | October 2022 | October 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17919415 | INJECTABLE OIL-BASED PHARMACEUTICAL COMPOSITION | October 2022 | October 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17995919 | 2-DEOXY-D-GLUCOSE FOR PREVENTION AND TREATMENT OF A VIRAL DISEASE, IN PARTICULAR OF COVID-19 | October 2022 | October 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17957707 | ACIDIC BONDING COMPOSITIONS AND METHODS FOR RESTORING AND COLOR TONING LIGHTENED HAIR | September 2022 | January 2025 | Allow | 27 | 3 | 1 | Yes | Yes |
| 17995254 | REMDESIVIR AND REMDESIVIR ANALOGS, SOLUTIONS, AND NANOPARTICLE, LIPOSOMAL, AND MICROPARTICLE COMPOSITIONS FOR TREATING VIRAL INFECTIONS | September 2022 | September 2025 | Allow | 36 | 1 | 0 | No | No |
| 17956528 | PHARMACEUTICAL FORMULATION CONTAINING A PSYCHEDELIC SUBSTANCE OBTAINED BY SELECTIVE LASER SINTERING (SLS) 3D PRINTING | September 2022 | August 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17911327 | THERAPEUTIC SYSTEM FOR THE TOPICAL, TRANSDERMAL AND TRANSCUTANEOUS APPLICATION OF CARBON MONOXIDE | September 2022 | January 2026 | Allow | 40 | 2 | 0 | Yes | No |
| 17905949 | Solid Deep Eutectic Solvent Formulation Platform | September 2022 | August 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17939690 | Crosslinking Submucosal Injectate System | September 2022 | August 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17909199 | MICROEMULSION-BASED VACCINE DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE THEREOF | September 2022 | December 2025 | Allow | 39 | 2 | 0 | No | No |
| 17884997 | Lipid Composition and Use Thereof for Delivery of a Therapeutically Active Agent to Endothelium | August 2022 | August 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17796599 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF MASTITIS | July 2022 | January 2026 | Allow | 41 | 2 | 0 | Yes | No |
| 17812746 | HEMOSTATIC NANOCAPSULES FOR STOPPING BLEEDING, VISUALIZING INJURY, AND DELIVERING DRUGS | July 2022 | August 2024 | Allow | 25 | 1 | 1 | No | No |
| 17864485 | MICROBEADS FOR EMBOLIZATION AND COMPOSITION FOR TREATING PROLIFERATIVE DISEASES | July 2022 | February 2026 | Abandon | 43 | 2 | 0 | No | No |
| 17787156 | KIT FOR PREPARING NANOPARTICLE COMPOSITION FOR DRUG DELIVERY, COMPRISING POLYLACTIC ACID SALT | June 2022 | October 2025 | Allow | 40 | 2 | 0 | No | No |
| 17843703 | FULLERENE GALLIUM PHOSPHONATE AND METHODS | June 2022 | June 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17755758 | USE OF OCTENYL-SUCCINATE STARCHES AS A BINDER IN WET GRANULATION | May 2022 | September 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17737982 | LIGHT STABLE SILVER CONTAINING NEAR NEUTRAL pH DISINFECTANT AND METHOD OF PREPARATION | May 2022 | August 2024 | Allow | 27 | 1 | 0 | No | No |
| 17774575 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | May 2022 | May 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17771856 | STABILIZED AMORPHOUS CALCIUM MAGNESIUM PHOSPHATE PARTICLE COMPOSITIONS | April 2022 | April 2025 | Allow | 35 | 0 | 1 | No | No |
| 17768621 | Microsphere-Drug Combination | April 2022 | September 2025 | Allow | 41 | 2 | 0 | No | No |
| 17768543 | PERSONAL CARE FORMULATION | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17766722 | MEMBRANE-BASED TWO COMPONENT THERAPEUTIC GAS RELEASE SYSTEM FOR ORAL ADMINISTRATION | April 2022 | November 2025 | Allow | 43 | 1 | 0 | No | No |
| 17765893 | THREE-DIMENSIONAL FLOW PATH STRUCTURE BODY AND NANOPARTICLE PRODUCTION METHOD USING SAME | April 2022 | May 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17764432 | ANTI-UV COSMETIC COMPOSITION | March 2022 | May 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17803220 | Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereof | March 2022 | January 2026 | Allow | 46 | 2 | 0 | No | No |
| 17761019 | ROPINIROLE-CONTAINING PATCH AND METHOD FOR IMPROVNG SKIN PERMEABILITY OF ROPINIROLE | March 2022 | January 2026 | Abandon | 46 | 3 | 0 | Yes | No |
| 17640749 | EXTRACELLULAR VESICLE-FENRETINIDE COMPOSITIONS, EXTRACELLULAR VESICLE-C-KIT INHIBITOR COMPOSITIONS, METHODS OF MAKING AND USES THEREOF | March 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17632669 | POLYMER COATING AGENT HAVING CONCURRENTLY EXCELLENT WATER AND OIL REPELLENT PROPERTIES AND COSMETIC COMPOSITION COMPRISING SAME SHOWING EXCELLENT MAKE-UP PERSISTENCY | February 2022 | August 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17632262 | LIPID NANOPARTICLE COMPOSITIONS COMPRISING CLOSED-ENDED DNA AND CLEAVABLE LIPIDS AND METHODS OF USE THEREOF | February 2022 | February 2026 | Abandon | 49 | 2 | 1 | No | No |
| 17630861 | NANOMATERIALS CONTAINING CONSTRAINED LIPIDS AND USES THEREOF | January 2022 | November 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17625659 | COSMETIC COMPOSITION CONTAINING GRAPHENE QUANTUM DOTS AS ACTIVE INGREDIENT | January 2022 | August 2025 | Allow | 44 | 3 | 0 | No | No |
| 17597280 | BIOCOMPATIBLE COMPOSITIONS COMPRISING A BIOCOMPATIBLE THICKENING POLYMER AND A CHITOSAN DERIVATIVE | December 2021 | August 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17597232 | ISOXAZOLINE COMPOUNDS AND USE THEREOF | December 2021 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17616346 | METHYLOBACTERIUM SP. NOV. STRAIN, COMPOSITIONS COMPRISING IT, AND ITS USE AS BIOSTIMULANT AND ENDOPHYTE NITROGEN-FIXING BACTERIUM | December 2021 | July 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17615967 | OIL-IN-WATER TYPE EMULSION LIP COSMETIC | December 2021 | June 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17595176 | DRY MICROPARTICLES | November 2021 | December 2025 | Abandon | 49 | 2 | 0 | No | No |
| 17595156 | LIPID NANOPARTICLE | November 2021 | May 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17609958 | MICROPARTICLES COMPRISING CELLULOSE NANOCRYSTALS AGGREGATED WITH PROTEINS AND COSMETIC USES THEREOF | November 2021 | December 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17437290 | EYE DROPS CONTAINING CHITOSAN NANOPARTICLES IN WHICH PDRN IS ENCAPSULATED, AND PREPARATION METHOD THEREFOR | November 2021 | May 2025 | Allow | 45 | 2 | 0 | No | No |
| 17606718 | PRODUCTS OF MANUFACTURE AND METHODS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICALS, ELECTROLYTES, AND NUTRICEUTICALS | October 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17605367 | LIPOSOMAL SUSTAINED-RELEASE COMPOSITIONS CONTAINING A THERAPEUTIC DRUG AND USE THEREOF | October 2021 | September 2025 | Allow | 47 | 3 | 0 | No | No |
| 17603339 | USE OF GOLD NANOCLUSTERS IN TREATING HYPERCHOLESTEROLEMIA OR HYPERCHOLESTEROLEMIA-ASSOCIATED DISEASES | October 2021 | May 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17601144 | ANTISEPTIC SKIN PREP COMPOSITION | October 2021 | April 2025 | Allow | 42 | 2 | 0 | No | No |
| 17600965 | SOLID NANOPARTICLE FORMULATION OF WATER INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD RIPENING AND IMMEDIATE DRUG RELEASE FOLLOWING INTRAVENOUS ADMINISTRATION | October 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17599753 | FROZEN, POROUS THIN FILMS AND METHODS OF MAKING AND USE THEREOF | September 2021 | October 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17593981 | PERSONAL CARE COMPOSITIONS AND METHODS COMPRISING TRANS-1-CHLORO-3,3,3-TRIFLUOROPROPENE AND TRANS-1,3,3,3-TETRAFLUOROPROPENE | September 2021 | April 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17598956 | COSMETIC COMPOSITION | September 2021 | June 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17599369 | POSS VISCOELASTIC HEMOSTATIC AGENTS | September 2021 | February 2026 | Allow | 52 | 4 | 0 | No | No |
| 17598515 | DRUG DELIVERY COMPOSITION | September 2021 | February 2026 | Allow | 53 | 3 | 1 | Yes | No |
| 17442949 | Method of Making Prodrug for Sustained and Controlled Release | September 2021 | November 2024 | Allow | 37 | 1 | 0 | No | No |
| 17442746 | Doxorubicin Containing Nanoplexes and Uses Thereof | September 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17441844 | BENZOXAZINE MONOMERS AND POLYMERIC COATINGS | September 2021 | October 2025 | Abandon | 49 | 2 | 1 | Yes | No |
| 17439911 | NANOPARTICLE, METHOD FOR PRODUCING NANOPARTICLE, AND PHARMACEUTICAL COMPOSITION | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17438892 | TRANSPARENT OR SEMITRANSPARENT INVERSE MICROLATICES OF POLYACRYLAMIDE AS OIL EMULSION DRIFT REDUCING AGENT | September 2021 | May 2025 | Allow | 44 | 2 | 0 | No | No |
| 17437442 | Supraparticle Formulations | September 2021 | October 2025 | Allow | 50 | 3 | 0 | No | No |
| 17435150 | HIGHLY STRUCTURED POROUS SILICA MATERIALS AND BIOLOGICAL USES THEREOF | August 2021 | August 2025 | Allow | 47 | 2 | 1 | No | No |
| 17433470 | MATERIAL AND SYSTEM FOR THE THERAPEUTIC TREATMENT OF JOINTS | August 2021 | October 2025 | Abandon | 50 | 4 | 0 | No | No |
| 17401654 | CIPROFLOXACIN POLYMORPH AND ITS USE | August 2021 | October 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17430497 | BIOBASED PEARLESCENT WAXES | August 2021 | April 2025 | Allow | 44 | 2 | 1 | No | No |
| 17400376 | Late-Stage Product Differentiation Process for Personal Care Products | August 2021 | June 2024 | Allow | 34 | 1 | 0 | Yes | No |
| 17430132 | LONG-ACTING PHOTORECEPTOR-BINDING NANOPARTICLES, AND COMPOSITIONS AND METHODS THEREOF | August 2021 | September 2025 | Allow | 49 | 3 | 0 | No | No |
| 17428256 | WOUND CONTACT LAYER AND DRESSING FOR IODINE DELIVERY | August 2021 | March 2026 | Allow | 55 | 5 | 0 | Yes | No |
| 17310351 | PARTICLES OF A MIXTURE OF IRON(III)-OXYHYDROXIDE, SUCROSE AND ONE OR MORE STARCHES, PREFERABLY OF SUCROFERRIC OXYHYDROXIDE | July 2021 | March 2025 | Allow | 43 | 1 | 1 | No | No |
| 17424780 | METHODS OF PREPARING LIPID NANOPARTICLES | July 2021 | January 2026 | Allow | 54 | 4 | 1 | Yes | No |
| 17423862 | Production and Use of Yeast Extract as a Medical Adjuvant | July 2021 | April 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17423380 | CHITOSAN-BASED NANOCOMPOSITE AS AN ANTIMICROBIAL AGENT AND CORROSION INHIBITOR | July 2021 | October 2025 | Allow | 51 | 4 | 1 | No | No |
| 17251521 | POLYION COMPLEX MICELLE THAT INCLUDES ANTISENSE OLIGONUCLEOTIDE AND BLOCK COPOLYMER OF PEG BLOCK AND CATIONIC POLYMER, SAID BLOCK COPOLYMER HAVING NUMBER-AVERAGE MOLECULAR WEIGHT OF 3-10 kDa | July 2021 | September 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17418616 | GEL-TYPE COSMETIC | June 2021 | November 2025 | Allow | 52 | 4 | 0 | Yes | No |
| 17417160 | OIL-IN-WATER TYPE PEST REPELLENT COMPOSITION | June 2021 | June 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17417263 | METHOD FOR CONTROLLING WEED | June 2021 | August 2024 | Abandon | 38 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIPPERT, JOHN WILLIAM.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LIPPERT, JOHN WILLIAM works in Art Unit 1615 and has examined 73 patent applications in our dataset. With an allowance rate of 56.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.
Examiner LIPPERT, JOHN WILLIAM's allowance rate of 56.2% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LIPPERT, JOHN WILLIAM receive 2.19 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LIPPERT, JOHN WILLIAM is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +36.1% benefit to allowance rate for applications examined by LIPPERT, JOHN WILLIAM. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.9% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.9% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.